19 January 2018 EMA/39932/2018 Information Management Division

Monthly statistics report: December 2017 Medicinal products for human use (cumulative figures for the year to date)

This document provides current information related to the volume and evaluation of marketing authorisation and post-authorisation applications for medicinal products for human use received by the European Medicines Agency. The purpose is only to provide ongoing factual information. Commentaries and analysis are provided in the Agency's annual reports.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Table 1. Pre-authorisation: Marketing-authorisation applications* 2014

2015

2016

2017†

Started Finalised Started Finalised Started Finalised Started Finalised

Non-orphan medicinal products

37

42

36

41

40

28

32

33

Advanced-therapy medicinal products

1

0

0

1

0

0

0

1

Paediatric-use (PUMA) products

0

1

1

0

1

1

2

1

Well-established use, abridged, hybrid and informed consent products

12

15

8

7

7

5

5

6

Generic products

25

6

28

25

24

22

10

22

3

3

12

2

14

7

17

14

78

67

85

76

86

63

66

77

20

17

24

20

27

16

19

20

1

1

1

1

1

2

4

1

99

85

110

97

114

81

89

98

New products

Similar biological products Sub-total product applications Orphan medicinal products◊ New products Advanced-therapy medicinal products Total product applications

* Finalised applications exclude applications withdrawn prior to opinion. † Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year. ◊ These figures reflect the orphan status of the medicinal products at the time of the CHMP opinion. EMA’s Committee for Orphan

Medicinal Products (COMP) then assesses whether the orphan designation should be maintained.

† Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.

Monthly statistics report: December 2017 EMA/39932/2018

Page 2/5

Table 2. Pre-authorisation: Outcome of the evaluation of marketing authorisation applications* 2014

2015

2016

2017†

81

93

79

92

Opinions recommending conditional marketing authorisation**

4

3

7

3

Opinions under exceptional circumstances**

1

3

1

2

Negative opinions

4

4

2

6

Opinions after accelerated assessment**

7

5

7

7

Applications withdrawn prior to opinion

6

5

16

14

Re-examinations requested

5

1

2

5

Re-examination - Positive opinions

1

0

2

0

Positive opinions

* Applicants can request a re-examination. The first four rows present the outcome of the evaluation before a re-examination (or a

re-consideration). The final row shows the number of changes from a negative to a positive opinion following a re-examination or a re-consideration. ** Included in the figures for positive opinions.

† Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.

† Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.

Monthly statistics report: December 2017 EMA/39932/2018

Page 3/5

Table 3. Scientific services 2014

2015

2017†

2016

Started Finalised Started Finalised Started Finalised Started Finalised

Compassionate-use opinions

1

1

0

0

0

0

0

0

Art. 58 (WHO) scientific opinions

1

1

1

1

0

1

1

0

0

1

1

1

0

0

2

1

16

16

17

19

19

22

22

24

Opinions on ancillary medicinal substances in medical devices* Plasma master file (includes initial certification, variations and annual re-certification)

* Consultation in accordance with Council Directive 93/42/EEC concerning medical devices as amended by Directive 2000/70/EC as

regards medical devices incorporating stable derivates of human blood or plasma and Directive 2001/14/EC. † Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.

Monthly statistics report: December 2017 EMA/39932/2018

Page 4/5

Table 4. Post-authorisation: Variations, renewals and annual reassessments 2014

2015

2016

2017†

Started

Finalised

Started

Finalised

Started

Finalised

Type IA variations

2,969

2,854

2,829

2,849

3,019

2,934

3,080 3,069

Type IB variations

1,886

1,986

1,954

1,838

2,000

1,988

2,054 1,975

Type II variations

1,151

1,103

1,168

1,097

1,185

1,131

1,133 1,116

Extensions of marketing authorisation

16

15

14

15

25

16

21

25

Annual reassessments

18

18

16

20

25

19

19

22

100

121

71

75

107

89

94

90

Renewals*

Started

Finalised

* Includes renewals of conditional marketing authorisations.

† Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.

Monthly statistics report: December 2017 EMA/39932/2018

Page 5/5

Medicinal products for human use: monthly figures - December 2017

Jan 19, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. Telephone +44 (0)20 3660 6000 ... This document provides current information related to the volume and evaluation of marketing authorisation and ... The purpose is only to provide ongoing factual information. Commentaries and ...

169KB Sizes 0 Downloads 259 Views

Recommend Documents

Medicinal products for human use: monthly figures - January 2017
Feb 11, 2016 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

Medicinal products for human use: monthly figures - January 2017
Feb 11, 2016 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

Monthly statistics report: May 2016: medicinal products for human use ...
Jun 22, 2016 - Information Management Division. Monthly ... This document provides current information related to the volume and evaluation of marketing.

monthly figures - December 2016 - European Medicines Agency
Jan 10, 2017 - Monthly statistics report: December 2016. EMA/18823/2017. Page 2/5. Table 1. Pre-authorisation: Marketing-authorisation applications*. 2013.

monthly figures - December 2016 - European Medicines Agency
Jan 10, 2017 - Applicants can request a re-examination. The first four rows present the outcome of the evaluation before a re-examination (or a.

Committee for Medicinal Products for Veterinary Use - European ...
Send a question via our website www.ema.europa.eu/contact. 15 July 2016 ... The Committee started a procedure for Lincocin and its associated names (lincomycin hydrochloride) from Zoetis. .... account the new information available.

Statement of the Committee for Medicinal Products for Veterinary Use ...
Dec 7, 2017 - Animal welfare is a value of the Union that is enshrined in Article 13 of the Treaty on the Functioning of the European Union (TFEU1). The use of animals in ... In conclusion, it is considered incumbent on marketing authorisation holder

monthly figures - October 2017 - European Medicines Agency
Oct 27, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. Telephone +44 (0)20 3660 6000 ... This document provides current information related to the volume and evaluation of marketing authorisation and ... The purpose

monthly figures - February 2017 - European Medicines Agency
Mar 16, 2017 - Applicants can request a re-examination. The first four rows present the outcome of the evaluation before a re-examination (or a.

Monthly Report - December 2017 - Public.pdf
Store Count. New stores. December 2017. Norilsk-1 Miass-1. Moscow 3-1 Moscow 0-7. Moscow 0-12 Korsakov-1. Yeisk-1 Ekaterinburg-4. Shlisselburg-1 Usinsk-1. Tikhoretsk-1 Mirnyi-1. Podolsk-1 Novorossiysk-2. Blagoveshchensk-2 Arkhangelsk-1. Kazan-3 Orekh

monthly figures - May 2017 - European Medicines Agency - Europa EU
Jun 21, 2017 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

monthly figures - March 2017 - European Medicines Agency - Europa ...
Apr 13, 2017 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

Opinion of the Committee for Medicinal Products for Veterinary Use on ...
Oct 6, 2016 - An agency of the European Union ... The scientific conclusions of the Committee are presented in the European public MRL assessment report.

Opinion of the Committee for Medicinal Products for Veterinary Use on ...
Oct 6, 2016 - The Committee, having considered the application and having ... The analytical method for monitoring of residues is appended to this opinion.

Opinion of the Committee for Medicinal Products for Veterinary Use on ...
Marker residue. Animal species. MRLs. Target tissues. Other provisions. Therapeutic classification. Aluminium ... Signature on file. Dr David Murphy. Chair, on ...

Opinion of the Committee for Medicinal Products for Veterinary Use on ...
Send a question via our website www.ema.europa.eu/contact ... The scientific conclusions of the Committee are presented in the European public MRL ...

Monthly report PDCO 12-15 December 2017 - European Medicines ...
Dec 15, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of ... submit data obtained through clinical studies with children be waived in all subsets of the paediatric population ... Fluorocholine (18F), EMEA

Draft guideline on the clinical investigation of medicinal products for ...
Jun 23, 2016 - From a regulatory point of view, the following goals of a therapy can be .... 360 multidimensional scales are preferred over specific physical QoL ...

beclometasone List of nationally authorised medicinal products ...
Sep 1, 2017 - E MA /594294/2017. P age 2 /22. Product Name (in authorisation country). MRP/DCP. Authorisation number. National Authorisation Number.

Guideline on the development of new medicinal products for the ...
Jun 28, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom ...... History of previous use of corticosteroids and 5-ASA is of little ...

Guideline on clinical investigation of new medicinal products for the
Jul 20, 2017 - Database Syst Rev. 2016 Mar 10;3:MR000043. Pogue J, Walter SD, Yusuf S. Evaluating the benefit of event adjudication of cardiovascular ...

Guideline on the development of new medicinal products for the ...
Jun 28, 2018 - ... Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom ..... intestine (e.g. capsule endoscopy) (small intestinal disease only).

Flupirtine-containing medicinal products - European Medicines Agency
Name of the product. Marketing Authorisation Holder. Country where product is authorised. Katadolon. Teva Pharma B.V.. Estonia. Flupirtinmaleat AbZ 100 mg Kapseln. AbZ-Pharma GmbH. Germany. Flupirtinmaleat AL 100 mg Hartkapseln. Aliud Pharma GmbH. Ge